review focu sharpen
apelli report result provid corpor updat
clinic program focu slight adjust guidanc top-lin data
pegasu announc expect januari vs decemb previous
timelin updat caus much surpris us matter week
month among compani file updat compani priorit
expans indic provid underscor thought recognit
leverag potenti achiev differenti clinic meaning benefit
commerci viabl therapeut area ahead present one
indic friday updat model
quarter stay bullish
gear pegasu top-lin januari encourag
potenti demonstr differenti benefit via hemoglobin
improv secondari endpoint surpris shift
could driven part addit patient enrol pegasu total
realist estim data collection/analysi holiday season
still keep ga mind approach complet phase enrol
top-lin result could becom largest driver base
high unmet neeed diseas area drug therapi recenti phase
readout iver yield question still draw attent area
continu believ remain underappreci
pipelin priorit focu cad trail expans
opportun await data upcom meet either debut initi
top-lin data nov and/or updat competit landscap
dec cad waiha longer remain priorit indic due
complex diseas etiolog combin approach could intrigu
top-lin debut friday american societi nephrolog meet
highlight eight patient treat system period week
work remain on-go across industri establish regulatori
pathway approv encourag initi earli result abstract
three patient demonstr target proteinuria reduct
updat model third-quart result adjust estim
accordingli includ model compani recent convert note
financ million conduct septemb apelli report cash
equival balanc million believ provid cash runway
year price histori
develop pegcetacoplan
current phase develop
pnh geograph atrophi ga
found apelli base
analyst certif import disclosur see disclosur
inhibit potenti address
two potenti blockbust indic signific unmet
need ga pnh believ potenti
address meaning proport pnh market
alreadi commerci develop alexion
therapeut soliri eculizumab ultomiri
ravulizumab ga howev treatment exist
sever late-stag diseas believ opportun set
eye could rival potenti exceed
regeneron flagship eylea aflibercept franchis
constrast also face brand ranibizumab/brolucizumab
demonstr hemoglobin improv least
improv secondari compar eculizumab phase
enrol phase derbi oak complet end
complement-depend
nephropathi nov
januari phase pegasu readout pnh
complet enrol phase ga studi
phase derbi oak readout ga
demonstr hemoglobin improv improv
transfus independ compar eculizumab phase
enrol phase derbi oak complet end
demonstr clinic signific benefit ga pnh
cad
employ composit valuat methodolog biotechnolog compani util revenu multipl discount cash flow analysi
respect development-stag compani place greater weight revenu multipl compar dcf analysi due
latter sensit long-run assumpt price target blend revenu multipl calcul dcf
valuat
appli revenu multipl pnh multipl ga lie rang industri averag
probabl success drug approv pnh ga
appli discount rate line smid-cap biotech
clinic efficaci fail meet clinic efficaci endpoint program pnh ga cad
clinic safeti safeti signal emerg clinic studi
manufactur risk manufactur issu could hinder regulatori approv limit penetr commerci market
regulatori risk regul rais addit requir concern around develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur develop asset could lower market potenti
negoti payor could limit market opportun
financ apelli may requir addit fund conduct addit studi commerci
statement oper
thousand except per share
good sold
research develop
loss extinguish debt
loss remeasur develop deriv liabil
loss remeasur fair valu warrant deriv
comprehens loss net tax
net profit loss per common share basic dilut
weight average common share basic dilut
thousand
cash equival
refund research develop credit
properti equip net
liabil stockhold equiti
current portion long-term debt
current portion right use liabil
addit paid capit
accumul comprehens incom
total liabil stockhold equiti
statement cashflow
thousand
loss earli extinguish debt
loss remeasur fair valu warrant
amort right-of-us asset
accret discount
refund research develop credit
net cash use oper activ
purchas properti equip
net cash use invest activ
issuanc seri convert prefer stock net issuanc
repay promissori note
payment cap call transact associ cost
proce issuanc common stock net issuanc cost
proce develop deriv liabil
proce exercis stock option warrant
proce issuanc term loan net issuanc cost
proce issuanc promissori note payabl
affili stockhold
proce issuanc common stock warrant
repay term loan
net cash provid financ activ
effect exchang rate chang cash cash equival
net increas decreas cash equival
cash equival begin period
cash equival end period
million
patient pnh
pnh patient treat
patient pnh
pnh patient treat
million
patient ga
ga patient treat
adult year age
patient ga
ga patient treat
popul
million except per share
/share total
assumpt multipl tab
nwc revenu
npv
million except per share
